Anne Lesage Sells 3,700 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anne Lesage sold 3,700 shares of Pharvaris stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $30.08, for a total value of $111,296.00. Following the completion of the transaction, the insider owned 56,450 shares in the company, valued at approximately $1,698,016. This represents a 6.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Anne Lesage also recently made the following trade(s):

• On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $580,992.00.
• On Thursday, April 30th, Anne Lesage sold 21,700 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $656,642.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $225,375.00.
• On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.

Pharvaris Stock Down 5.1%

NASDAQ:PHVS traded down $1.57 during mid-day trading on Friday, reaching $29.44. 512,191 shares of the company’s stock traded hands, compared to its average volume of 245,049. Pharvaris N.V. has a 12-month low of $14.59 and a 12-month high of $31.14. The company has a 50 day moving average price of $27.62 and a 200-day moving average price of $26.03.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). Sell-side analysts anticipate that Pharvaris N.V. will post -3.19 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. Geode Capital Management LLC grew its holdings in shares of Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. Legal & General Group Plc grew its holdings in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the period. Amundi grew its holdings in shares of Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Pharvaris by 19.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares during the period.

Wall Street Analysts Forecast Growth

PHVS has been the topic of a number of research analyst reports. Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Royal Bank Of Canada reduced their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.